Ben Sasse has no in-news role in the supplied facts. In this brief, note: a new pancreatic cancer drug approval is not tied to Sasse. Biographic context: U.S. senator, former university president, conservative scholar.
The FDA has approved daraxonrasib (Rasonque), a once-daily pill from Revolution Medicines, for adults with metastatic pancreatic cancer who have received prior therapy or cannot take combination chemotherapy. A 500‑patient trial has shown median survival of 13.2 months versus 6.7 months for chemotherapy; a 30‑day supply will cost about $39,800 and expanded access has already treated thousands.